The growing popularity of GLP-1 receptor agonists, especially semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), both of which are FDA-approved for type 2 diabetes and/or obesity and, has been accompanied by considerable social media attention and discussion, from which thorough analyses of user-generated data have emerged highlighting reductions in alcohol-seeking motivation, decreased drinking behavior, and altered subjective responses to alcohol (Arillotta et al
Development Status as of July 2026 Likewise, research programs can change rapidly
Adderall is commonly used for attention deficit hyperactivity disorder (ADHD)
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS
Nonrandomized database studies have inherent limitations